Ok thanks. The updated results will carry a lot of weight.
The first round of results didn’t meet the primary objective of PFS but the secondary objectives of OS shows a significant improvement and quality of life is improved.
I’m wondering why all the analyst reports keep talking about an AIPAC ph3. The company hasn’t made any announcement about this, unless I missed something.
Also, if the AIPAC ph2b was enough for EMA registration
why is there even talk of a ph3?
is it that results aren’t quite good enough to justify the risk of a therapy not fully tested?. The recent results in other Efti trials will help. We wait in hope of the updated AIPAC results getting us over the line.
- Forums
- ASX - By Stock
- IMM
- News: IMM Immutep Receives FDA And Irb Approval In The Us For Phase Iib Tacti-003 Trial In Hnscc
News: IMM Immutep Receives FDA And Irb Approval In The Us For Phase Iib Tacti-003 Trial In Hnscc, page-18
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMM (ASX) to my watchlist
|
|||||
Last
31.0¢ |
Change
-0.010(3.13%) |
Mkt cap ! $464.8M |
Open | High | Low | Value | Volume |
31.5¢ | 31.5¢ | 30.5¢ | $64.53K | 207.6K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
5 | 12538 | 31.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
31.5¢ | 17897 | 7 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
5 | 12538 | 0.310 |
13 | 174407 | 0.305 |
9 | 91620 | 0.300 |
7 | 85929 | 0.295 |
7 | 73965 | 0.290 |
Price($) | Vol. | No. |
---|---|---|
0.315 | 17897 | 7 |
0.320 | 135653 | 7 |
0.325 | 52350 | 7 |
0.330 | 200738 | 7 |
0.335 | 84133 | 3 |
Last trade - 10.12am 12/08/2024 (20 minute delay) ? |
Featured News
IMM (ASX) Chart |